📰 Action Trial News
Action Trial News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Action Trial. Real-time updates on events, politics, business and more.
February 14, 2024
The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.
September 16, 2023
The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.
August 7, 2023
Improving the Lives of Those Affected by Cancer August 2023 Forward-Looking Statements This...
June 6, 2023
Advancing our Mission to Improve the Lives of Those Affected by Cancer June 2023 Forward-Looking Statements ... | June 6, 2023
June 4, 2023
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microe...
May 3, 2023
- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023
March 1, 2023
01.03.2023 - - Achieved $31.3 Million in Net Revenue from Sales of COSELA (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - - Announced Top Line Results from Pivotal Phase 3 ...
August 3, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.